Literature DB >> 15792651

Unintended pregnancies with the etonogestrel implant (Implanon): a case series from postmarketing experience in Australia.

Mira Harrison-Woolrych1, Richard Hill.   

Abstract

This paper describes a case series of over 200 unintended pregnancies associated with the etonogestrel implant, Implanon. These cases have been reported to the Australian Adverse Drug Reactions Advisory Committee during the first 3 years of marketing in this country. Of 218 cases included, 45 had insufficient data to assess the reason for contraceptive failure and 46 women were determined to have been already pregnant prior to Implanon insertion. Of the remaining 127 cases, the most common reason for unintended pregnancy was failure to insert the implant in 84 women. Other reasons included incorrect timing of insertion (19 cases), expulsion of Implanon (3 cases) and interaction with hepatic enzyme-inducing medicines (8 cases). The remaining 13 cases were classified as product/method failures once other reasons had been excluded. Using the 204,486 Implanon devices subsidized in this period to estimate the population exposed and the 218 pregnancies reported, the approximate failure rate in postmarketing use was 1 in 1000 insertions. These findings (and reports to medical indemnity insurers) have resulted in the development of guidelines and training for doctors inserting Implanon in Australia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15792651     DOI: 10.1016/j.contraception.2004.10.005

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  14 in total

Review 1.  Efficacy and safety of long-acting reversible contraception.

Authors:  Amy Stoddard; Colleen McNicholas; Jeffrey F Peipert
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

2.  Increasing body mass index or weight does not appear to influence the association between efavirenz-based antiretroviral therapy and implant effectiveness among HIV-positive women in western Kenya.

Authors:  Rena C Patel; Beatrice Jakait; Katherine Thomas; Constantin Yiannoutsos; Maricianah Onono; Elizabeth A Bukusi; Kara K Wools-Kaloustian; Craig R Cohen
Journal:  Contraception       Date:  2019-06-24       Impact factor: 3.375

3.  Etonogestrel contraceptive implant failure in a woman taking rifampin: a case report.

Authors:  Tesfaye H Tufa; Abraham Fessehaye; Ferid A Abubeker
Journal:  Contracept Reprod Med       Date:  2022-05-05

Review 4.  Current and future contraceptive options for women living with HIV.

Authors:  Rena C Patel; Elizabeth A Bukusi; Jared M Baeten
Journal:  Expert Opin Pharmacother       Date:  2017-09-19       Impact factor: 3.889

5.  Implanon: subdermal single rod contraceptive implant.

Authors:  Pushpa Bhatia; Sangita Nangia; Shivani Aggarwal; Chitra Tewari
Journal:  J Obstet Gynaecol India       Date:  2011-09-28

Review 6.  Concomitant contraceptive implant and efavirenz use in women living with HIV: perspectives on current evidence and policy implications for family planning and HIV treatment guidelines.

Authors:  Rena C Patel; Chelsea Morroni; Kimberly K Scarsi; Tabitha Sripipatana; James Kiarie; Craig R Cohen
Journal:  J Int AIDS Soc       Date:  2017-05-11       Impact factor: 5.396

7.  Examining the efficacy, safety, and patient acceptability of the etonogestrel implantable contraceptive.

Authors:  Heather Hohmann
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

Review 8.  Safety and Benefits of Contraceptives Implants: A Systematic Review.

Authors:  Morena Luigia Rocca; Anna Rita Palumbo; Federica Visconti; Costantino Di Carlo
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-08

9.  Decreased efficacy of an etonogestrel implant in a woman on antiepileptic medications: a case report.

Authors:  Jill Lange; Stephanie Teal; Kristina Tocce
Journal:  J Med Case Rep       Date:  2014-02-11

Review 10.  Complications of Subcutaneous Contraception: A Review.

Authors:  Rebecca C Ramdhan; Emily Simonds; Charlotte Wilson; Marios Loukas; Rod J Oskouian; R Shane Tubbs
Journal:  Cureus       Date:  2018-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.